Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant

CLN 35.3.11

Canadian active & maintenance modified pentasa study
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT00603733
Ulcerative Colitis
5-Aminosalicylate
Source : Importé depuis le centre
Active Ulcerative Colitis
Remission of Ulcerative Colitis
Recrutement fermé
Dernière modification : 2016/04/20
Type de recherche

Interventionnel

Médicament expérimental

PHASE3


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Active Ulcerative Colitis

Remission of Ulcerative Colitis

Source : Importé depuis le centre

Profil des participants

Donnée non disponible

Critères de sélection

Critères d'inclusion

Inclusion Criteria for Active phase:

* Newly diagnosed or recurrent, mild to moderate Ulcerative Colitis patients.
* Extent of colonic involvement confirmed within the past 36 months
* UCDAI score of at least 3 but not greater than 8 and a score of at least 1 for endoscopy
* Screening tests to rule out any abnormalities in stool, heart or kidney.
* Male or non-pregnant females between 18 to 75 years.
* Women of childbearing potential to use efficacious contraception as judged by the investigator.
* Written informed consent given.

Inclusion Criteria for Maintenance phase:

* Newly recruited subjects with documented mild to moderate UC entering the Run-in Phase: in clinical remission for at least 1 month and for a maximum of 3 years, and receiving 5-ASA 1.4 to 2.5 g/day for maintenance of quiescent disease
* Subjects from Active Phase: meeting remission criteria after the 8-week active period
* Extent of colonic involvement confirmed within the past 36 months by colonoscopy
* In complete remission at entry into the Maintenance Phase, defined as i) a score of 0 or 1 for stool frequency; ii) a score of 0 for rectal bleeding; iii) a score of 0 for endoscopy findings; and iv) a Physician's Global Assessment (PGA) score of 0 or 1
* Screening tests to rule out any abnormalities in stool, heart or kidney.

Exclusion Criteria:

* Use of 5-ASA products at a dose \>2.5g/day within 7 days prior to entry.
* Proctitis, short bowel syndrome, prior bowel surgery, severe UC, other forms of Inflammatory Bowel Disease
* Infectious diseases, parasites, bacterial pathogens
* Allergy to aspirin or salicylate
* Liver or kidney abnormalities
* Alcohol or drug abuse
* Pregnancy
* Cancer
* Bleeding disorders, ulcers, autoimmune diseases
* Mental disorders
* Participation in clinical trial in last 30 days
* Inability to fill in diary cards / comply with protocol requirements

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Pentasa® modified extended release Donnée non disponible 5-ASA (5-Aminosalicylate)
  • Inconnu
  • Pentasa® Donnée non disponible 5-ASA (5-Aminosalicylate)
  • Inconnu
  • Pentasa® modified extended release
    État du recrutement
    unknown
    Pentasa®
    État du recrutement
    unknown
    Données à jour depuis : 20 avril 2016

    Description de l'étude

    Résumé de l'étude

    The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative Colitis (UC) and also in maintenance of quiescent disease.

    Source : Importé depuis le centre

    A multi-centre, randomized, double-blind, non-inferiority trial comparing the efficacy and safety of a new modified oral extended release Pentasa® (mesalamine) 500 mg tablet to the currently marketed Pentasa® (mesalamine) 500 mg tablet in subjects with active mild to moderate ulcerative colitis treated with 4 g/day for 8 weeks and in maintenance of remission of ulcerative colitis in subjects treated with 2 g/day for 24 weeks. The study involves male or non-pregnant female subjects aged 18 to 75 years.

    Subjects were randomised on entry into the trial, and if they were in remission at the end of the 8-week Active Phase or the 4-week Run-in Phase, they were eligible for enrolment into the 24-week Maintenance Phase, remaining on the original randomised treatment.

    Source : Importé depuis le centre

    Sites

    Centres participants

      10 affichés sur 27 centres
    • CENTRE HOSPITALIER UNIVERSITAIRE DE QUÉBEC

      Québec

      QUÉBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • CENTRE UNIVERSITAIRE DE SANTÉ MCGILL

      Montréal

      QUÉBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • ALPHA RECHERCHE CLINIQUE INC.

      Loretteville

      QUEBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • BARRIE GI ASSOCIATES

      Barrie

      ONTARIO, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • CASTLEDOWNS MEDICENTRE

      Edmonton

      ALBERTA, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • DIGESTIVE HEALTH CLINIC

      Richmond hill

      ONTARIO, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • HILYARD PLACE BUILDING A

      Saint john

      NEW BRUNSWICK, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • HOPITAL MAISSONNEUVE ROSEMONT

      Montreal

      QUEBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • HOTEL DIEU DE LEVIS

      Levis

      QUEBEC, CANADA

      Recrutement local
      État du recrutement: FERMÉ
    • HOTEL DIEU GRACE HOSPITAL

      Windsor

      ONTARIO, CANADA

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 20 avril 2016
    Données à jour depuis : 27 fév.
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT00603733